Skip to main content

Advertisement

SpringerLink
Log in

Prostate Cancer Microbiome: A Narrative Review of What We Know So Far

  • MICROBIAL ANTI-CANCER THERAPY AND PREVENTION (Y YAMAUCHI, SECTION EDITOR)
  • Published:
Current Clinical Microbiology Reports Aims and scope Submit manuscript

Abstract

Purpose of review

The role of the microbiome in mediating the pathogenesis of prostate cancer has been suggested to have a role in the carcinogenesis process. This review aimed to explore the potential role of the prostate, urinary, and gut microbiomes in prostate cancer development.

Recent Findings

Current literature indicates that the discovery of microbes, potentially associated with prostate cancer, raises more questions about whether their presence was merely coincidental or due to contamination. Studies have discovered bacteria and viruses in the prostate, urinary tract, and gastrointestinal tract. However, whether there is a prostate microbiome is still unclear due to the study design limitations and small sample size.

Summary

Even though the link between the specific microbiome and prostate cancer has not been established, findings suggest that chronic inflammation and immune system modulation associated with the microbiome are the underlying mechanisms increasing the risk of prostate cancer development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14:e1002533.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13:260–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Malard F, Dore J, Gaugler B, et al. Introduction to host microbiome symbiosis in health and disease. Mucosal Immunol. 2021;14:547–54.

    Article  CAS  PubMed  Google Scholar 

  4. Wheeler KM, Liss MA. The microbiome and prostate cancer risk. Curr Urol Rep. 2019;20:1–9.

    Article  Google Scholar 

  5. Benson AK, Kelly SA, Legge R, et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci. 2010;107:18933–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chen C, Huang X, Fang S, et al. Contribution of host genetics to the variation of microbial composition of cecum lumen and feces in pigs. Front Microbiol. 2018;9:2626.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474:1823–36.

    Article  CAS  PubMed  Google Scholar 

  8. Porter CM, Shrestha E, Peiffer LB, et al. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:345–54.

    Article  CAS  PubMed  Google Scholar 

  9. Olejniczak-Staruch I, Ciążyńska M, Sobolewska-Sztychny D, et al. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2021;22:3998.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med. 2021;290(2):257–78.

    Article  CAS  PubMed  Google Scholar 

  11. Benahmed AG, Gasmi A, Doşa A, et al. Association between the gut and oral microbiome with obesity. Anaerobe. 2021;70:102248.

    Article  Google Scholar 

  12. Young C, Wood HM, Seshadri RA, et al. The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries. Genome Med. 2021;13:1–13.

    Article  CAS  Google Scholar 

  13. Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol. 2013;1:3.

    PubMed  PubMed Central  Google Scholar 

  14. Peisch SF, Van Blarigan EL, Chan JM, et al. Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol. 2017;35:867–74.

    Article  CAS  PubMed  Google Scholar 

  15. Klein CA. Cancer progression and the invisible phase of metastatic colonization. Nat Rev Cancer. 2020;20:681–94.

    Article  CAS  PubMed  Google Scholar 

  16. Hui L, Chen Y. Tumor microenvironment: Sanctuary of the devil. Cancer Lett. 2015;368:7–13.

    Article  CAS  PubMed  Google Scholar 

  17. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61–8.

    Article  CAS  PubMed  Google Scholar 

  18. Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67:326–44.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67:226–36.

    Article  CAS  PubMed  Google Scholar 

  20. Massari F, Mollica V, Di Nunno V, et al. The human microbiota and prostate cancer: friend or foe? Cancers (Basel). 2019;11:459.

    Article  CAS  Google Scholar 

  21. Ocáriz-Díez M, Cruellas M, Gascón M, et al. Microbiota and lung cancer. Opportunities and challenges for improving immunotherapy efficacy. Front Oncol. 2020;10:1945.

  22. • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. Prostate cancer is the one of the most common cancers among men in the world.

  23. Hayward SW, Cunha GR. The prostate: development and physiology. Radiol Clin North Am. 2000;38:1–14.

    Article  CAS  PubMed  Google Scholar 

  24. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256–69.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Tomas D, Krušlin B, Rogatsch H, et al. Different types of atrophy in the prostate with and without adenocarcinoma. Eur Urol. 2007;51:98–104.

    Article  PubMed  Google Scholar 

  26. Estemalik J, Demko C, Bissada NF, et al. Simultaneous detection of oral pathogens in subgingival plaque and prostatic fluid of men with periodontal and prostatic diseases. J Periodontol. 2017;88:823–9.

    Article  CAS  PubMed  Google Scholar 

  27. Kadosh E, Snir-Alkalay I, Venkatachalam A, et al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature. 2020;586:133–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. OhadianMoghadam S, Momeni SA. Human microbiome and prostate cancer development: current insights into the prevention and treatment. Front Med. 2021;15:11–32.

    Article  Google Scholar 

  29. Huycke MM, Gaskins HR. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp Biol Med. 2004;229:586–97.

    Article  CAS  Google Scholar 

  30. Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, et al. Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol. 2012;3:448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kelly SP, Anderson WF, Rosenberg PS, et al. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus. 2018;4:121–7.

    Article  PubMed  Google Scholar 

  32. Conteduca V, Crabb SJ, Jones RJ, et al. Persistent neutrophil to lymphocyte ratio> 3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS One. 2016;11:e0158952.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Che B, Zhang W, Xu S, Yin J, He J, Huang T, Li W, Yu Y, Tang K. Prostate microbiota and prostate cancer: a new trend in treatment. Front Oncol. 2021;11.

  34. Abidi SH, Bilwani F, Ghias K, et al. Viral etiology of prostate cancer: genetic alterations and immune response. A literature review. Int J Surg. 2018;52:136–40.

    Article  PubMed  Google Scholar 

  35. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Cancer Netw. 2016;14:19–30.

  36. Zarei A, Javid H, Sanjarian S, et al. Metagenomics studies for the diagnosis and treatment of prostate cancer. Prostate. 2022;82:289–97.

    Article  PubMed  Google Scholar 

  37. Chilakapati SR, Ricciuti J, Zsiros E. Microbiome and cancer immunotherapy. Curr Opin Biotechnol. 2020;65:114–7.

    Article  CAS  PubMed  Google Scholar 

  38. •• Golombos DM, Ayangbesan A, O’Malley P, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018;111:122–128. The study reported the enrichment of several bacteria in the feces of prostate cancer and BPH patients.

  39. •• Shrestha E, White JR, Yu S-H, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 2018;199:161–171. This is the most comprehensive study to date regarding the male urinary microbiome and its association with prostate cancer. These results suggest the presence of pro-inflammatory bacteria and pathogens in the urinary tract of prostate cancer patients.

  40. •• Hochreiter WW, Duncan JL, Schaeffer AJ. Evaluation of the bacterial flora of the prostate using a 16S rRNA gene based polymerase chain reaction. J Urol. 2000;163:127–130. This is one of the first studies evaluating the bacterial flora of the prostate using a 16S rRNA gene-based polymerase chain reaction.

  41. •• Cavarretta I, Ferrarese R, Cazzaniga W, et al. The microbiome of the prostate tumor microenvironment. Eur Urol. 2017;72:625–631. They discovered significant differences in specific microbial populations among tumor or peri-tumor and non-tumor prostate specimens.

  42. Shinohara DB, Vaghasia AM, Yu S, et al. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate. 2013;73:1007–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. •• Glassing A, Dowd SE, Galandiuk S, et al. Inherent bacterial DNA contamination of extraction and sequencing reagents may affect interpretation of microbiota in low bacterial biomass samples. Gut Pathog. 2016;8:1–12. The study suggested the possibility of bacterial DNA contamination, which may affect the interpretation of microbiota in low bacterial biomass samples.

  44. Ghosh SK, Feng Z, Fujioka H, et al. Conceptual perspectives: Bacterial antimicrobial peptide induction as a novel strategy for symbiosis with the human host. Front Microbiol. 2018;9:302.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Eisenhofer R, Minich JJ, Marotz C, et al. Contamination in low microbial biomass microbiome studies: issues and recommendations. Trends Microbiol. 2019;27:105–17.

    Article  CAS  PubMed  Google Scholar 

  46. •• Feng Y, Ramnarine VR, Bell R, et al. Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics. 2019;20:1–8. This is the first human prostate microbiome study with an integrated metagenomics and metatranscriptomics approach. They discovered a non-sterile microenvironment in the prostate of prostate cancer patients, but they did not find a link between the microbiome and cancer local progression. There is however evidence that pseudomonas infection may impede metastasis.

  47. •• Banerjee S, Alwine JC, Wei Z, et al. Microbiome signatures in prostate cancer. Carcinogenesis 2019;40:749–764. Viral and helicobacter involvements are believed to affect the expression of several cellular genes associated with oncogenic processes.

  48. • Al-Marhoon MS, Ouhtit A, Al-Abri AO, et al. Molecular evidence of Helicobacter pylori infection in prostate tumors. Curr Urol. 2014;8:138–143. This is the first study that provided molecular evidence of H. pylori DNA presence in the prostatic tissue of BPH and prostate cancer patients.

  49. Markowski MC, Boorjian SA, Burton JP, et al. The microbiome and genitourinary cancer: a collaborative review. Eur Urol. 2019;75:637–46.

    Article  PubMed  Google Scholar 

  50. Namiki K, Goodison S, Porvasnik S, et al. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One. 2009;4:e6872.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Miyake M, Ohnishi K, Hori S, et al. Mycoplasma genitalium infection and chronic inflammation in human prostate cancer: detection using prostatectomy and needle biopsy specimens. Cells. 2019;8:212.

    Article  CAS  PubMed Central  Google Scholar 

  52. Huang W-Y, Hayes R, Pfeiffer R, et al. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Prev Biomarkers. 2008;17:2374–81.

    Article  CAS  Google Scholar 

  53. •• Yu H, Meng H, Zhou F, et al. Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia. Arch Med Sci AMS. 2015;11:385. There are changes in the microbial population in EPS, urine, and seminal fluid between BPH and prostate cancer, suggesting a potential role for the bacteria in two different conditions.

  54. Samanta M, Harkins L, Klemm K, et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170:998–1002.

    Article  PubMed  Google Scholar 

  55. Fioriti D, Videtta M, Mischitelli M, et al. The human polyomavirus BK: Potential role in cancer. J Cell Physiol. 2005;204:402–6.

    Article  CAS  PubMed  Google Scholar 

  56. Ahn J, Barber GN. STING signaling and host defense against microbial infection. Exp Mol Med. 2019;51:1–10.

    Article  PubMed  Google Scholar 

  57. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer. 2010;10:1–7.

    Article  CAS  Google Scholar 

  58. Cortes GA, Flores JL. Physiology, Urination. StatPearls [Internet]. 2020.

  59. Aragon IM, Herrera-Imbroda B, Queipo-Ortuño MI, et al. The urinary tract microbiome in health and disease. Eur Urol Focus. 2018;4:128–38.

    Article  PubMed  Google Scholar 

  60. Neugent ML, Hulyalkar NV, Nguyen VH, et al. Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. MBio. 2020;11:e00218-20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Scott RP, Quaggin SE. The cell biology of renal filtration. J Cell Biol. 2015;209:199–210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Vervaet BA, D’Haese PC, Verhulst A. Environmental toxin-induced acute kidney injury. Clin Kidney J. 2017;10:747–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Safwat AS, Hasanain A, Shahat A, et al. Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: A randomized, comparative study. World J Urol. 2019;37:1347–52.

    Article  CAS  PubMed  Google Scholar 

  64. Sfanos KS, Yegnasubramanian S, Nelson WG, et al. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 2018;15:11–24.

    Article  PubMed  Google Scholar 

  65. Shoskes DA, Altemus J, Polackwich AS, et al. The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome and controls as well as between patients with different clinical phenotypes. Urology. 2016;92:26–32.

    Article  PubMed  Google Scholar 

  66. Bajic P, Dornbier RA, Doshi CP, et al. Implications of the genitourinary microbiota in prostatic disease. Curr Urol Rep. 2019;20:1–10.

    Article  Google Scholar 

  67. Javier-DesLoges J, McKay RR, Swafford AD, Sepich-Poore GD, Knight R, Parsons JK. The microbiome and prostate cancer. Prostate Cancer Prostatic Dis. 2021;1–6.

  68. Matsushita M, Fujita K, Motooka D, et al. The gut microbiota associated with high-Gleason prostate cancer. Cancer Sci. 2021;112:3125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Fan X, Jin Y, Chen G, et al. Gut microbiota dysbiosis drives the development of colorectal cancer. Digestion. 2021;102:508–15.

    Article  CAS  PubMed  Google Scholar 

  70. •• Alanee S, El-Zawahry A, Dynda D, et al. A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. Prostate. 2019;79:81–87. The microbiota of urine in patients with prostate cancer tends to cluster separately without the disease, however further studies are required to investigate the role of the urinary microbiome as a biomarker.

  71. Jain S, Dash P, Minz AP, et al. Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-κB activation and recurrent dexamethasone administration fails to suppress it in vivo. Prostate. 2019;79:168–82.

    Article  CAS  PubMed  Google Scholar 

  72. Lessard L, Begin LR, Gleave ME, et al. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005;93:1019–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Katz R, Ahmed MA, Safadi A, et al. Characterization of fecal microbiome in biopsy positive prostate cancer patients. BJUI Compass. 2022;3:55–61.

    Article  Google Scholar 

  74. •• Liss MA, White JR, Goros M, et al. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur Urol. 2018;74:575–582. Microbiome may have slight influences on prostate cancer, but they are likely patient-specific, thus requiring a further paired analysis and precise manipulation.

  75. Lan T, Park Y, Colditz GA, et al. Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2020;31:891–904.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12:661–72.

    Article  CAS  PubMed  Google Scholar 

  77. Casero RA, Stewart TM, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer. 2018;18:681–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Tsoi T-H, Chan C-F, Chan W-L, et al. Urinary polyamines: a pilot study on their roles as prostate cancer detection biomarkers. PLoS One. 2016;11:e0162217.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Arora HC, Eng C, Shoskes DA. Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. Ann Transl Med. 2017;5(2).

  80. Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers (Basel). 2019;11:1174.

    Article  CAS  Google Scholar 

  81. Gori S, Inno A, Belluomini L, et al. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Crit Rev Oncol Hematol. 2019;143:139–47.

    Article  PubMed  Google Scholar 

  82. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (80- ). 2013;342:971–976.

  83. Spanogiannopoulos P, Bess EN, Carmody RN, et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016;14:273–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Vázquez-Baeza Y, Callewaert C, Debelius J, et al. Impacts of the human gut microbiome on therapeutics. Annu Rev Pharmacol Toxicol. 2018;58:253–70.

    Article  PubMed  CAS  Google Scholar 

  85. Borgo F, Macandog AD, Diviccaro S, et al. Alterations of gut microbiota composition in post-finasteride patients: a pilot study. J Endocrinol Invest. 2021;44:1263–73.

    Article  CAS  PubMed  Google Scholar 

  86. Harada N, Hanaoka R, Hanada K, et al. Hypogonadism alters cecal and fecal microbiota in male mice. Gut Microbes. 2016;7:533–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. •• Sfanos KS, Markowski MC, Peiffer LB, et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018;21:539–48. The study speculated that oral hormonal therapies for prostate cancer may influence GI microbitoa and clinical response. Thus antitumor effects of immunotherapy may also be affected. However, further studies are required.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Daisley BA, Chanyi RM, Abdur-Rashid K, et al. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat Commun. 2020;11:1–11.

    CAS  Google Scholar 

  89. Samykutty A, Shetty AV, Dakshinamoorthy G, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Gnanasekar M. Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evidence-Based Complement Altern Med. 2013;2013.

  90. • Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science (80- ). 2018;359:91–97. Primary resistance of immune checkpoint inhibitors (ICIs) may be affected by abnormal gut microbiome composition, which may be influenced by antibiotics.

  91. Anker JF, Naseem AF, Mok H, et al. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun. 2018;9:1–14.

    Article  CAS  Google Scholar 

  92. Karstens L, Asquith M, Caruso V, et al. Community profiling of the urinary microbiota: considerations for low-biomass samples. Nat Rev Urol. 2018;15:735–49.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Not applicable.

Author information

Authors and Affiliations

  1. Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia

    Yudhistira Pradnyan Kloping & Lukman Hakim

  2. Dr. Soetomo General-Academic Hospital, Surabaya, East Java, Indonesia

    Yudhistira Pradnyan Kloping

  3. Universitas Airlangga Teaching Hospital, Surabaya, East Java, Indonesia

    Lukman Hakim

Authors
  1. Yudhistira Pradnyan Kloping
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lukman Hakim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lukman Hakim.

Ethics declarations

Conflict of Interest

Yudhistira Pradnyan Kloping and Lukman Hakim declare that they have no conflicts of interest.

Informed Consent

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Microbial Anti-cancer Therapy and Prevention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kloping, Y.P., Hakim, L. Prostate Cancer Microbiome: A Narrative Review of What We Know So Far. Curr Clin Micro Rpt 9, 1–8 (2022). https://doi.org/10.1007/s40588-022-00178-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40588-022-00178-y

Keywords

Search

Navigation